1 / 17

Special Considerations: When and What to Start with Viral Hepatitis Coinfections

Special Considerations: When and What to Start with Viral Hepatitis Coinfections. Joseph J. Eron, Jr, MD Professor of Medicine University of North Carolina at Chapel Hill. FINAL: 07-20-12. Presented by JJ Eron, Jr , MD, IAS, July 25, 2012. HCV and HIV – When and What to Start.

Download Presentation

Special Considerations: When and What to Start with Viral Hepatitis Coinfections

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Special Considerations: When and What to Start with Viral Hepatitis Coinfections Joseph J. Eron, Jr, MDProfessor of MedicineUniversity of North Carolina at Chapel Hill FINAL: 07-20-12 Presented by JJ Eron, Jr, MD, IAS, July 25, 2012.

  2. HCV and HIV – When and What to Start • RM is a 62 yo AA MSM who had a h/o injection drug use in 1970’s. • He only accepted his sexual orientation in the last 5 years after divorcing his wife. Since that time he has had multiple male sex partners and also consumed more alcohol than his typical 7-10 drinks per week. He has not injected drugs in 40 years. • He presents to you after an evening of drinking when he vomited a modest about of blood

  3. HCV and HIV – When and What to Start • He is found to have HCV genotype 1a and an HCV VL of 2,700,000 c/mL, his HBV surface Ag is negative and surface Ab is positive • He is HIV+ with CD4 of 850/µL and VL of 8,000 c/mL • On endoscopy he has small varices and no other abnormalities • His AST is 90 and ALT 110, INR is 1.4 and albumin is 3.3. Plt count is 110. He has no ascites by exam and RUQ US and his liver is small and nodular appearing • His HIV genotype shows K103N

  4. What is your next step for his HCV after getting him to stop alcohol intake? • Obtain a liver biopsy • Obtain a transient elastography • Obtain an IL28b genotype • None of the above – he needs to be treated no matter what the results are • Something else

  5. You are confident that he needs HCV treatment but his hepatologist does a biopsy any way. Path is read as F3/4 but when pushed pathologist say more 4 than 3. He has decreased his drinking substantially and is on propranolol. What do you do now? • Begin HCV therapy with interferon alfa and ribavirin lead-in and boceprevir • Begin HCV therapy with telaprevir, interferon alfa, and ribavirin • Begin HIV therapy first • Something else

  6. You decide that he should begin HIV therapy first and will start HCV therapy once HIV RNA is suppressed. Which NRTI combination will you choose? (HIV RNA 8,000 c/mL, CD4 850/µL and TDR with K103N) • TDF/FTC • ABC/3TC • ZDV/3TC • Something else

  7. You decide that he should begin HIV therapy first and will start HCV therapy once HIV RNA is suppressed. If you chose TDF/FTC which cART regimen would you start? (HIV RNA 8,000 c/mL, CD4 850/µL and TDR with K103N) • FDC TDF/FTC/efavirenz • FDC TDF/FTC/ rilpivirine • FDC TDF/FTC/cobisistat/elvitegravir • FDC TDF/FTC and raltegravir • FDC TDF/FTC and atazanavir/r • FDC TDF/FTC and darunavir/r • Something else

  8. You chose TDF/FTC and raltegravir (despite Dr. Eron’s concern re TDR).What HCV therapy will you start when he gets suppressed? • Interferon alfa and ribavirin lead-in and boceprevir • Telaprevir, interferon alfa, and ribavirin • Wait for the next approved drug (12 months or so) • Something else

  9. HCV and HIV – When and What to Start • On HIV therapy HIV RNA falls to < 50 c/mL with 8 weeks and his CD4 increases to 900/µL. • However he presents with nausea and vomiting and his AST rises to 459 and ALT to 600, bilirubin rises slightly to 1.2 (was 0.8) and INR = 1.5.

  10. What do you do? • Freak and call JurgenRockstroh • Continue treatment with weekly labs • Stop HIV therapy and wait for AST/AST to decline and then restart TDF/FTC ATV/r (or similar) • Stop HIV therapy and wait for AST/AST to decline and treat his HCV • Get a liver biopsy • Something else

  11. HIV and HBV Presented by JJ Eron, Jr, MD, IAS, July 25, 2012.

  12. HBV and HIV – What to Start • Robin M is Latina and 35 yo who was recently diagnosed with HIV and HBV. She has had one male partner who is also HIV and HBV infected and unfortunately they do not always use condoms. He is currently suppressed on therapy but previously had failed a regimen of ZDV/3TC and EFV in 2005 or 2006 after several years of therapy. • Robin M has been avoiding HIV and HBV testing for fear of a positive test. She has obesity (BMI 34), HTN and DM. Her last BP was 138/88 mmHg on lisinopril (ACE) and her last HgbA1C was 6.5% on metformin.

  13. HBV and HIV – What to Start • Her CD4 cell counts is 358/µL with an HIV RNA of 320,000 c/mL • Her HBV viral load is 12,000,000 IU/mL and AST is 58 and ALT 70 IU/mL. INR, albumin and platelets are normal • Her eGFR is 40 mL/min and she has 2+ protein and 2+ glc on UA with a urine prot/creatinine ratio of 800

  14. A pre-therapy HIV genotype shows M41L and T215DWould you obtain an HBV resistance genotype? • Yes • No • Not sure

  15. HBV and HIV – What to Start • You decide to get a HBV resistance test even though you are not 100% sure how it will effect your therapy choice. • The results show the well-desribedrt M204V/I plus rt L180M mutations associated with lamivudine resistance.

  16. Which antiviral combination will you begin? • FDC EFV/TDF/FTC • TDF/FTC every other day with a recommended third agent • TDF/FTC every other day with a recommended third agent plus entecavir • ABC/3TC daily with a recommended third agent • ABC/3TC daily with a recommended third agent plus entecavir • Something else

  17. If you chose to add entecavir what dose would you choose? • 0.5 mg daily • 1.0 mg daily • No tengo la menor idea!

More Related